Abstract: The present invention provides a resin composition which is highly sensitive and exhibits high chemical resistance even in the case of being baked at a low temperature of 250° C. or less and can suppress the generation of outgas after curing. The present invention is a resin composition which contains (a) an alkali-soluble resin containing polyimide, polybenzoxazole, polyamide-imide, a precursor of any one of these compounds and/or a copolymer of these compounds and (b) an alkali-soluble resin having a monovalent or divalent group represented by the following general formula (1) in a structural unit and in which the modification rate of a phenolic hydroxyl group in the alkali-soluble resin (b) is 5% to 50%. (In general formula (1), O represents an oxygen atom. R1 represents a hydrogen atom or a hydrocarbon group which has 1 to 20 carbon atoms and may be substituted and R2 represents an alkyl group having 1 to 5 carbon atoms. s and t each independently represent an integer from 0 to 3.

Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

Abstract: A method of treating a substrate in a pressure vessel that includes the steps: preparing an ion-exchange bath with a bath composition that comprises a polar solvent and a plurality of ion-exchanging ions in a vessel; submersing a substrate having an outer region containing a plurality of exchangeable ions in the bath; pressurizing the bath in the vessel to a predetermined pressure substantially above ambient pressure; heating the bath in the vessel to a predetermined temperature; and treating the substrate for a predetermined ion-exchange duration at the predetermined pressure and temperature such that a portion of the plurality of exchangeable ions is exchanged with a portion of the ion-exchanging ions. The substrate can consist essentially of a glass, glass-ceramic or ceramic substrate composition, and the predetermined ion-exchange duration, temperature and pressure can each be selected based at least in part on the substrate composition and the bath composition.

Abstract: The present application relates to crystalline solid forms of an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t, including methods of preparation thereof, and intermediates in the preparation thereof, where the compound is useful in the treatment of diseases such as cancer.

Abstract: The invention provides novel methods of synthesizing new monofunctional and/or multifunctional heterocyclic monomers and the formulation of new alloys of said monomers from base reactants via a continuous solvent-free, or alternatively in-solvent, one-step high shear reactor methodology designed to reduce the minor isomer formation and to eliminate the need for post-processing purification, as well as the ability to disperse reinforcements and additives while synthesizing such heterocyclic monomers and monomer alloys created and to the synthesis of related compositions.

Abstract: The invention provides novel methods of synthesizing new monofunctional and/or multifunctional heterocyclic monomer and prepolymer alloys via a continuous solvent-free, or alternatively in-solvent, one-step high shear reactor methodology designed to eliminate the need for post-processing purification and react monomer to predictable conversions, as well as the synthesis of related compositions. Additionally, the invention allows the dispersion of reinforcements and additives while synthesizing heterocyclic monomers and formulating heterocyclic prepolymer alloys.

Abstract: Described is a system and method for detecting whether a biological event has occurred in a cellular sample, and then activating a fluidics system to fix the cell at the point in time with the event occurred. In one example, a sample preparation system includes a camera linked to a confocal microscope that is interrogating a cellular sample. Once a detectable event, such as a binding event, has occurred, the sample preparation system releases a fixative to fix the cell at the point in time when the event was detected.

Abstract: The present invention pertains to Method for monitoring a dialysis treatment of a patient, preferably for monitoring a haemodialysis, haemodiafiltration and/or peritoneal dialysis treatment of a patient, the method including the steps of: irradiating a sample of a dialysis fluid used in the dialysis treatment with linearly polarized irradiation light; detecting the intensity of the fluorescence light emitted by the dialysis fluid in a first polarization plane; detecting the intensity of the fluorescence light emitted by the dialysis fluid in a second polarization plane which is different from the first polarization plane; determining the anisotropy of the fluorescence light emitted by the dialysis fluid; and determining the concentration of at least one fluorophore in the dialysis fluid on the basis of both, the determined anisotropy and the intensity of the fluorescence light emitted by the dialysis fluid.

Abstract: Production of a conjugated diene rubber includes polymerizing isoprene or a monomer mixture containing isoprene and an aromatic vinyl monomer in an inert solvent by using a polymerization initiator so as to form a polymer block (A) having an active end, mixing the polymer block (A) having an active end and 1,3-butadiene or a monomer mixture containing 1,3-butadiene and an aromatic vinyl monomer to continue a polymerization reaction so as to obtain a conjugated diene polymer chain having an active end and containing a polymer block (A) and a polymer block (B), and reacting a compound represented by the following general formula (1) with the active end of the conjugated diene polymer chain having an active end:

Abstract: A difunctional polyhedral oligomeric silsesquioxane derivative and synthesis of the present invention is disclosed. The difunctional polyhedral oligomeric silsesquioxane derivative is represented by following formula (I), wherein R is selected from one of and The synthesis of the difunctional polyhedral oligomeric silsesquioxane derivative includes obtaining bis-PA-DDSQ compound though addition reaction of DDSQ compound and 4-acetoxystyrene, obtaining bis-Ph-DDSQ compound though hydrolytic reaction of bis-PA-DDSQ compound and hydrazine, and obtaining bis-AlBz-DDSQ compound though cycloaddition reaction of bis-Ph-DDSQ compound and paraformaldehyde.

Abstract: A primer composition is provided. The primer composition includes at least one bi- or multi-functional benzoxazine compound; and at least one compound including a functional group having affinity for a metallic surface, and a cross-linkable group. A method of forming a primer layer on a semiconductor device, and a method of encapsulating a semiconductor device are also provided.

Abstract: Embodiments of the present disclosure provide for methods of making an organoboron compound, organoboron compounds, and the like.

Abstract: The invention relates to low-viscosity polymers containing silane groups, the polymers curing rapidly under the effect of moisture to form an elastic material with good heat resistance and being in particular suitable for elastic adhesives and sealants. The polymers containing silane groups are based on special hydoxysilanes which carry a secondary OH group. They are in particular obtained by reacting epoxysilanes with secondary amines.

Abstract: This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

Abstract: An amino-siloxane composition is presented. The amino-siloxane composition includes structure (I): wherein R1 is independently at each occurrence a C1-C5 aliphatic radical; R2 is a C3-C4 aliphatic radical; R3 is a C1-C5 aliphatic radical or R4, wherein R4 comprises structure (II): and X is an electron donating group. Methods of reducing an amount of carbon dioxide in a process stream using the amino-siloxane composition are also presented.

Abstract: Described herein are precursors and methods for forming silicon-containing films. In one aspect, the precursor comprises a compound represented by one of following Formulae A through E below: In one particular embodiment, the organoaminosilane precursors are effective for a low temperature (e.g., 350° C. or less), atomic layer deposition (ALD) or plasma enhanced atomic layer deposition (PEALD) of a silicon-containing film. In addition, described herein is a composition comprising an organoaminosilane described herein wherein the organoaminosilane is substantially free of at least one selected from the amines, halides (e.g., Cl, F, I, Br), higher molecular weight species, and trace metals.

Abstract: Oligonucleotide analogues comprising boronic acid and/or boronic ester moieties are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.

Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.

Abstract: The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, D and R2 are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.

Abstract: Described herein are precursors and methods for forming silicon-containing films. In one aspect, there is provided a precursor of Formula I: wherein R1 is selected from linear or branched C3 to C10 alkyl group, linear or branched C3 to C10 alkenyl group, linear or branched C3 to C10 alkynyl group, C1 to C6 dialkylamino group, electron withdrawing group, and C6 to C10 aryl group; R2 is selected from hydrogen, linear or branched C1 to C10 alkyl group, linear or branched C3 to C6 alkenyl group, linear or branched C3 to C6 alkynyl group, C1 to C6 dialkylamino group, C6 to C10 aryl group, linear or branched C1 to C6 fluorinated alkyl group, electron withdrawing group, and C4 to C10 aryl group; optionally wherein R1 and R2 are linked together to form ring selected from substituted or unsubstituted aromatic ring or substituted or unsubstituted aliphatic ring; and n=1 or 2.

Abstract: A compound according to a formula I and devices incorporating the same are described. The compound according to the formula I can have the structure: wherein X is Si or Ge; R1 and R2 represent mono, di, tri, tetra, or penta substitutions or no substitution; R3, R4 represent mono, di, tri, or tetra substitutions or no substitution; R1 and R2 are optionally joined to form a ring, which may be further substituted; L is a single bond or comprises an aryl or heteroaryl group having from 5-20 carbon atoms, which is optionally further substituted; and A is an aromatic group. A contains a group selected from the group consisting of indole, carbazole, benzofuran, dibenzofuran, benzothiophene, dibenzothiophene, benzoselenophene, dibenzoselenophene, triphenylene, azacarbazole, azadibenzofuran, azadibenzothiophene, azadibenzoselenophene, azatriphenylene, and combinations thereof, which are optionally further substituted. The device can include the compound according to Formula I in an organic layer.

Abstract: Compounds according to Formula I and Formula II are potent inhibitors of Arginase I and II activity: where R1, R2, R3, R4, R5, R6, R7, R8, R9, D, M, X, and Y are defined as set forth in the specification. The invention also provides pharmaceutical compositions of the compounds and methods of their use for treating or preventing a disease or a condition associated with arginase activity.

Abstract: Embodiments of the present disclosure provide for methods of making an organoboron compound, organoboron compounds, and the like.

Abstract: The inventive compounds are small molecule therapeutics that are potent inhibitors of Arginase I and II activity. The invention also provides pharmaceutical compositions of the inventive compounds and methods for using the inventive compounds for treating or preventing a disease or a condition associated with arginase activity.

Abstract: The invention provides a family of fluorescent compounds. The compounds are substituted silaxanthenium compounds that can be chemically linked to one or more biomolecules, such as a protein, nucleic acid, and therapeutic small molecule. The compounds can be used for imaging in a variety of medical, biological and diagnostic applications. The dyes are particularly useful for in vitro, in vivo and ex vivo imaging applications.

Abstract: A reactive ionic liquid to be used as an ionic component that is contained in an ion-containing layer in a transducer arranged in contact with a high-resistance layer as a dielectric layer of the transducer, and is restrained from migrating from the ion-containing layer to the high-resistance layer on application of a voltage is provided. The reactive ionic liquid comprises an ion pair that consists of an anion and a cation. In the reactive ionic liquid, (a) the anion comprises (a1) a reactive group that consists of an alkoxysilyl group and (a2) an anionic group consisting of a carboxylate (—COO?) group or a sulfonate (—SO3?) group. (b) The cation (b1) consists of an imidazolium, ammonium, pyrrolidinium, morpholinium, or phosphonium cation, and (b2) does not comprise an N—H group or a P—H group.

Abstract: The present invention provides compounds of formula wherein is wherein is and electrophoretic devices comprising the compounds of formula (1A) or (1B).

Abstract: Hair treatment agents include at least one 4-morpholino-methyl-substituted silicone, which comprises in each case at least one of the structural units of the formulae (I), (II) and (III) as described herein, where * is a bond to one of the structural units (I), (II) or (III) or an end group B (Si-bound) or D (O-bound); B represents a group —OH, —O—Si(CH3)3, —O—Si(CH3)2OH, —O—Si(CH3)2OCH3; D represents a group —H; —Si(CH3)3, —Si(CH3)2OH, —Si(CH3)2OCH3; A represents an O-bound structural unit (I), (II) or (III) or an O-bound oligomeric or polymeric radical including structural units of the formulae (I), (II) or (III) or half of a connecting O atom to a structural unit (III) or represents —OH; n, m and o represent whole numbers between 1 and 1000.

Abstract: The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, each of R1 and R2, R3 and R7 of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III.

Abstract: The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Abstract: Described herein are organoaminosilane precursors which can be used to deposit silicon containing films which contain silicon and methods for making these precursors. Also disclosed herein are deposition methods for making silicon-containing films or silicon containing films using the organoaminosilane precursors described herein. Also disclosed herein are the vessels that comprise the organoaminosilane precursors or a composition thereof that can be used, for example, to deliver the precursor to a reactor in order to deposit a silicon-containing film.

Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

Abstract: Prochelator compounds of Formula I or Formula II: are described, along with methods of using the same and pharmaceutical formulations or compositions containing the same.

Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Abstract: The invention relates to compounds of formula I (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including inhibition of kinase activity such as PI-3 kinase.

Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Abstract: The present invention relates to compounds of a general formula (I) having photoluminescence properties. The present invention also relates to applications, such as protein imaging tools, involving such compounds.

Abstract: Compounds and methods of treating anti-inflammatory conditions are disclosed.

Abstract: The present invention relates to novel Fused Tricyclic Silyl Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, M1, X1 and X2 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Silyl Compound, and methods of using the Fused Tricyclic Silyl Compounds for treating or preventing HCV infection in a patient.

Abstract: Described herein are precursors and methods for forming silicon-containing films. In one aspect, there is provided a precursor of Formula I: wherein R1 is selected from linear or branched C3 to C10 alkyl group, linear or branched C3 to C10 alkenyl group, linear or branched C3 to C10 alkynyl group, C1 to C6 dialkylamino group, electron withdrawing group, and C6 to C10 aryl group; R2 is selected from hydrogen, linear or branched C1 to C10 alkyl group, linear or branched C3 to C6 alkenyl group, linear or branched C3 to C6 alkynyl group, C1 to C6 dialkylamino group, C6 to C10 aryl group, linear or branched C1 to C6 fluorinated alkyl group, electron withdrawing group, and C4 to C10 aryl group; optionally wherein R1 and R2 are linked together to form ring selected from substituted or unsubstituted aromatic ring or substituted or unsubstituted aliphatic ring; and n=1 or 2.

Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.

Abstract: Embodiments of the invention provide methods and materials for chemical cross-coupling reactions that utilize aryl alcohol derivatives as cross-coupling partners. Embodiments of the invention include methods for the amination of aryl sulfamates and carbamates, which are attractive cross-coupling partners, particularly for use in multistep synthesis. Illustrative embodiments include versatile means to use simple derivatives of phenol as precursors to polysubstituted aryl amines, as exemplified by a concise synthesis of the antibacterial drug linezolid.

Abstract: The present disclosure invention relates to novel secondary aminosilanes, a method for producing same, and the use thereof. The secondary aminosilanes can be produced from readily available reactants in a simple manner. The secondary aminosilanes are characterized for example by a low viscosity and are well suited for producing silane-functional polymers that have a low viscosity, fast curing, and good thermal stability.

Abstract: The present invention relates to photochromic materials that include a photochromic compound that includes a photochromic substituent (e.g., an indeno-fused naphthopyran) and at least one pendent silane group, which is bonded to the photochromic substituent. The pendent silane groups are selected from certain pendent siloxy-silane groups and/or pendent alkoxy-silane groups represented by general formulas (I) and/or (II) as described in further detail herein. The present invention also relates to photochromic articles, such as photochromic optical elements (e.g., photochromic lenses), and photochromic coating compositions (e.g., curable photochromic coating compositions), that include the photochromic materials of the present invention. The photochromic materials of the present invention have improved compatibility with compositions into which they may be incorporated, for example, coating compositions, such as urethane coating compositions.

Abstract: The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Abstract: Asymmetric bifunctional silyl (ABS) monomers comprising covalently linked pharmaceutical, chemical and biological agents are described. These agents can also be covalently bound via the silyl group to delivery vehicles for delivering the agents to desired targets or areas. Also described are delivery vehicles which contain ABS monomers comprising covalently linked agents and to vehicles that are covalently linked to the ABS monomers. The silyl modifications described herein can modify properties of the agents and vehicles, thereby providing desired solubility, stability, hydrophobicity and targeting.

Abstract: The embodiments described herein generally relate to compositions and articles including dye compounds having desirable optical properties, and related methods. In some cases, the compositions and articles may possess advantageous optical properties, including various degrees of absorbance, emission, and/or transmission at particular wavelengths or ranges of wavelength. Embodiments described herein may be useful as optical filters in protective eyewear applications.

Abstract: This invention relates to the use of benzimidazole boronic acid derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K?, PI3K?, and/or PI3K?. Suitably, the present invention relates to the use of benzimidazole boronic acids in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3K? selective benzimidazole boronic acid compounds for treating cancer.